Trading
Data
Solutions
Insights
About
Resilience was founded in 2020 by Drew Oetting, Patrick Yang, Sandesh Mahatme, and Rahul Singhvi. The company has not publicly endorsed plans to participate in an IPO.
Resilience is a biotechnology company focused on streamlining manufacturing processes for complex medicines. The company has entered into a number of strategic partnerships, including with The University of Texas MD Anderson Cancer Center, Harvard University, Children’s Hospital of Philadelphia, and Be Biopharma. Per a company press release, Resilience has "secured more than $2 billion in equity financing since its founding." The company did not disclose valuation figures following a $625 million Series D funding round in 2022.
These comments should not be interpreted to mean that the company is formally pursuing or foregoing an IPO.
Resilience is a privately held company and is not publicly traded on NYSE or NASDAQ in the U.S. To buy pre-IPO shares of a private company, you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
If you own Resilience pre-IPO shares and are considering selling, you can find what your shares could be worth on Forge’s secondary marketplace.
Our Private Market Specialists are available to answer any questions you might have and can help connect you with a buyer from our network of 125,000 accredited investors and institutions. You can also learn more about how to sell your private shares before getting started.
Resilience is a private company and not publicly traded.
If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
| Date | Funding Round | Funding Raised | Price per Share | Last Known Valuation |
|---|---|---|---|---|
| 6/6/2022 | Series D | $625MM raised | $XXX.XX | $XXX.XX |
| 5/15/2021 | Series C | $600MM raised | $XXX.XX | $XXX.XX |
| 11/23/2020 | Series B | $755MM raised | $XXX.XX | $XXX.XX |
| 4/17/2020 | Series A-1 and A-2 | $54.28MM raised | $XXX.XX | $XXX.XX |
